A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure

NCT00001962 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

100

Enrollment

NIH

Sponsor class

Stopped DSMB recommended closing the study and publishing the results

Conditions

Aplastic Anemia
Pure Red Cell Aplasia
Diamond Blackfan Anemia

Interventions

DRUG: Daclizumab

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)